NeoGenomics Reports Third Quarter 2026 Results
Business Wire•28/10/2026•16:05 ET
0
Key Highlights
- ➤Revenue $209 million, up 11% year over year
- ➤Clinical revenue $195 million, up 13%; NGS revenue grew 29%
- ➤Adjusted EBITDA $19 million, up 53% year over year
- ➤NeoGenomics raised FY 2026 revenue guidance to $807-$809 million
- ➤Warren Stone becomes CEO January 4, 2027; Tony Zook transitions to Executive Chairman
Expert Statements
Tony Zook, Chief Executive Officer of NeoGenomics
“Our third-quarter results reinforce that we have the right strategy in place and the right team to execute against it.”
Tony Zook, Chief Executive Officer of NeoGenomics
“Clinical revenue growth of 13% continues to showcase the strength of our broad-based testing solutions portfolio, with NGS revenue growing a strong 29% and NGS test volume growing 17%.”
Tony Zook, Chief Executive Officer of NeoGenomics
“As our business continues its shift to higher-value, high-margin testing modalities, we see further opportunity to invest into our commercial teams, community channel strength, and product pipeline.”
Tony Zook, Chief Executive Officer of NeoGenomics
“At the same time, we expect to reduce complexity across our business through operational excellence initiatives designed to deliver accelerating growth and disciplined margin expansion over the long-term.”
Clinical services revenue grew 13%, with NGS revenue growth of 29%
Company raises full-year 2026 revenue and adjusted EBITDA guidance
Get started
Create a free account to read the full story.